- Title
- The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201
- Creators
- Susana N Banerjee - Royal Marsden NHS Foundation TrustEls Van Nieuwenhuysen - VIB-KU Leuven Center for Cancer BiologyCarol Aghajanian - Memorial Sloan Kettering Cancer CenterVéronique D'Hondt - Institut du Cancer de Montpellier (ICM) Val d'Aurelle Parc Euromedecine, Oncologie Médicale, GINECO, Montpellier, FranceBradley J Monk - Florida Cancer Specialists & Research InstituteAndrew Clamp - The Christie NHS Foundation TrustEmily Prendergast - Minnesota OncologyAna Oaknin - Vall d'Hebron Hospital UniversitariKari Ring - University of VirginiaNicoletta Colombo - European Institute of OncologyRobert W Holloway - Florida Hospital Cancer InstituteManuel Rodrigues - Institut CurieHye Sook Chon - Moffitt Cancer CenterCharlie Gourley - Edinburgh Cancer ResearchAlessandro D Santin - Yale UniversityPremal H Thaker - Washington University in St. LouisChristine Gennigens - Centre Hospitalier Universitaire de LiègeGregg Newman - Sansum Medical ClinicErin Salinas - Nebraska Cancer SpecialistsHagop Youssoufian - VerastemKathleen N Moore - University of Oklahoma Health Sciences CenterStephanie Lustgarten - VerastemDavid M O'Malley - The Ohio State UniversityToon Van Gorp - KU LeuvenRachel N Grisham - Memorial Sloan Kettering Cancer Center
- Publication Details
- Future oncology (London, England), p.1
- Identifiers
- 991006241234902656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201
Future oncology (London, England), p.1
12/12/2025
PMID: 41384753
Related links
Metrics
1 Record Views